LFVN Lifevantage Corporation

$LFVN Back to 4. Will buy at support. Not up here. Earnings was not good Q4 2026 revenue down 23.1% year over year to $42.4 million Fiscal 2026 revenue down 20.1% to $182.6 million versus $228.5 million Fiscal 2026 diluted EPS declined to $0.40 from $0.75 Adjusted EBITDA decreased to $13.7 million from $22.1 million in 2025 Gross margin compression to 77.6% from 80.4% due to inventory obsolescence and mix Total active accounts fell 21.2% to 104,000 from 132,000 No fiscal 2027 guidance issued due to CEO transition

LifeVantage reported fiscal Q4 and full-year 2026 results after the market close, triggering a sharp negative reaction from investors. The company entered the report with already weakened fundamentals after several quarters of declining performance. In fiscal Q3 2026, revenue fell 25.2% YoY to $43.7 million, while diluted EPS dropped to $0.11 from $0.26 a year earlier. Revenue missed analyst estimates by 8.5%, while EPS came in 35% below expectations. Institutional sentiment also deteriorated, with 68 investors reducing their positions versus 39 increasing them. BlackRock cut its stake by 65.1%, selling more than 501,000 shares, while Geode Capital Management reduced its position by 53.7%. The broader market provided little support, with the S&P 500 down 0.1% and the Nasdaq off 0.2%. Analysts expect LifeVantage revenue to decline an average of 5.4% annually over the next three years, contrasting with projected 3.7% annual growth for the broader U.S. personal-care products industry $LFVN

$LFVN Q4 '26 Earnings Results & Recap • Reported GAAP EPS of $0.11 down -35.29% YoY • Reported revenue of $42.38M down -23.10% YoY